Actualités

Hims & Hers has made clear its interest in the peptides. It owns a peptide manufacturer and said it “sees meaningful potential” in the drugs.

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Investor Jonah Lupton said peptide market forecasts may be "too conservative," citing growing consumer interest.

Hims & Hers Health Inc. (NYSE:HIMS) is one of the 10 Stocks Stealing the Spotlight from Wall Street Giants. Hims & Hers rallied by 12.49 percent on Monday to finish at $30.17 apiece, as investors cheered rosy growth prospects for the obesity market, alongside its efforts to bridge the gap between the rapidly increasing demand […]

In recent days, Hims & Hers Health, Inc. amended its revolving credit agreement to support the completed acquisition of Australian telehealth company Eucalyptus and appointed longevity-focused physician Dr. Anant Vinjamoori as Chief Medical Officer for the Hims brand. These steps coincide with a pivot toward branded GLP-1 weight loss drugs, including a new GLP-1-based weight loss membership aimed at longer-term patient relationships. By combining an expanded international footprint,...

In April, the stock faced resistance near $30 and saw selling pressure in the following weeks.

Suja Life, Inc. (Nasdaq: SUJA) debuted last month, offering investors exposure to the leading platform for natural healthy beverages Vertically-integrated model produces drinks from farm to bottle in about a week, with almost all produced and sourced in California near Suja’s campus and over 400k points of distribution Brands include #1 cold pressed juice maker Suja […] The post Fuel Up Your Portfolio with Suja Life’s Farm-to-Bottle Growth Strategy appeared first on ExecEdge.

Doximity (DOCS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Scott Galloway and Ed Elson laid out the math on Prof G Markets and it should make every fast food shareholder uneasy: roughly 30 million Americans, about 1 in 8 US adults, are now on GLP-1s, and the drugs are reducing fast food’s addressable market by an estimated 27-30%. This is structural, not cyclical: appetite, ... The GLP-1 stock nobody is pricing in isn’t a drugmaker

Hims & Hers Health expanded its Hims & Hers Benefits program with eight new partners, adding subscriber-only perks across fitness, nutrition, women's health, metabolic monitoring, and AI-powered coaching. The expanded program introduces broader whole-body health services that go beyond the company's core telehealth offerings. Hims & Hers Health (NYSE:HIMS) is trading at $27.78 and the stock is down 16.9% year to date, after a decline of 51.7% over the past year. Over a three-year period the...

Hims & Hers Health, Inc. (HIMS) closed at $27.71 in the latest trading session, marking a -4.38% move from the prior day.

OMCL vs. HIMS: Which Stock Is the Better Value Option?

Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is HIMS a good stock to buy? We came across a bearish thesis on Hims & Hers Health, Inc. on Valueinvestorsclub.com by Pridwen. In this article, we will summarize the bears’ thesis on HIMS. Hims & Hers Health, Inc.’s share was trading at $27.51 as of June 2nd. HIMS’s trailing and forward P/E were 57.14 and 58.82 […]

Hims & Hers Health (NYSE:HIMS) has appointed Dr. Anant Vinjamoori as Chief Medical Officer of the Hims brand. The appointment highlights a push into longevity, preventive health, and peptide based care. Dr. Vinjamoori brings experience in clinical medicine, advanced diagnostics, and AI supported longevity programs from prior health technology roles. For investors tracking NYSE:HIMS, the appointment comes with the stock at a share price of $28.01, a three year return of 206.1%, and a five...

TD Cowen expects around 59 million patients worldwide to be using GLP-1 therapies by the end of the decade, up sharply from its previous estimate of 46 million.

Competition is intensifying after WeightWatchers' Med+ program became available through LillyDirect.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

Canaccord said the FDA's review of compounded peptides could create a regulatory catalyst for the category.

What recent performance says about Hims & Hers Health (HIMS) With no single headline event driving attention, Hims & Hers Health (HIMS) has drawn interest as investors weigh its recent share performance, current valuation metrics, and the latest snapshot of its financial profile. Over the past day, the stock declined 0.9%, while it gained 15.3% over the past week and 0.4% over the past month. Over the past 3 months, the share price rose 67.2%, though the year to date return is down 17.7% and...

U.S. Senator Jim Banks has publicly urged the FDA to review Hims & Hers Health’s GLP-1 advertising, pricing, and subscription practices. The request puts fresh political and regulatory attention on the company’s weight management telehealth model and its GLP-1 offerings. This scrutiny arrives as the company’s GLP-1 franchise has become more visible to consumers and investors. For investors tracking NYSE:HIMS, this political focus comes at a time when the stock trades around $27.51 and has...

The Eucalyptus deal supports Hims' goals of $6.5 billion in revenue and $1.3 billion EBITDA by 2030.

The deal adds telehealth operations in Australia, Canada and Japan.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.2% and the actively tr

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Hims & Hers Health (NYSE:HIMS) has completed the acquisition of Eucalyptus. The deal extends the company’s presence into Japan, Germany, Canada, and Australia. Eucalyptus brings established consumer brands and clinical infrastructure in weight management and whole body care. Hims & Hers Health runs a direct to consumer telehealth and wellness platform, connecting patients with licensed clinicians and tailored treatment plans. By bringing Eucalyptus under its umbrella, the company now has a...

HIMS expands its integrated telehealth ecosystem with a new weight-loss membership and a planned Eucalyptus acquisition to broaden virtual care.

Hims & Hers Health (NYSE:HIMS) has launched generic semaglutide in Canada following a key patent lapse, marking its first GLP-1 offering outside the United States. Hims & Hers Health is also expanding its Hims & Hers Benefits program, aiming to bundle access to medications with broader wellness services. Management is positioning these moves as part of a push into new international markets and more comprehensive care offerings. Hims & Hers Health, known for its telehealth platform focused...

CEO Andrew Dudum said Hims is building "an entire health ecosystem" rather than serving as a solution for a single health condition.